Abstract：
People who inject drugs (PWID) are at risk of invasive infections such as bloodstream infections, endocarditis, osteomyelitis and septic arthritis. Such infections require prolonged antibiotic therapy, but there is limited evidence about the optimal care model to deliver to this population. The Epidemiology and Management of invasive infections among people who Use drugs (EMU) study aims to (1) describe the current burden, clinical spectrum, management and outcomes of invasive infections in PWID; (2) determine the impact of currently available models of care on completion of planned antimicrobials for PWID admitted to hospital with invasive infections and (3) determine postdischarge outcomes of PWID admitted with invasive infections at 30 and 90 days.
EMU is a prospective multicentre cohort study of Australian public hospitals who provide care to PWIDs with invasive infections. All patients who have injected drugs in the previous six months and are admitted to a participating site for management of an invasive infection are eligible. EMU has two components: (1) EMU-Audit will collect information from medical records, including demographics, clinical presentation, management and outcomes; (2) EMU-Cohort will augment this with interviews at baseline, 30 and 90 days post-discharge, and data linkage examining readmission rates and mortality. The primary exposure is antimicrobial treatment modality, categorised as inpatient intravenous antimicrobials, outpatient antimicrobial therapy, early oral antibiotics or lipoglycopeptide. The primary outcome is confirmed completion of planned antimicrobials. We aim to recruit 146 participants over a 2-year period.
EMU has been approved by the Alfred Hospital Human Research Ethics Committee (Project number 78815.) EMU-Audit will collect non-identifiable data with a waiver of consent. EMU-Cohort will collect identifiable data with informed consent. Findings will be presented at scientific conferences and disseminated by peer-review publications.
ACTRN12622001173785; Pre-results.
EMU is a prospective multicentre cohort study of Australian public hospitals who provide care to PWIDs with invasive infections. All patients who have injected drugs in the previous six months and are admitted to a participating site for management of an invasive infection are eligible. EMU has two components: (1) EMU-Audit will collect information from medical records, including demographics, clinical presentation, management and outcomes; (2) EMU-Cohort will augment this with interviews at baseline, 30 and 90 days post-discharge, and data linkage examining readmission rates and mortality. The primary exposure is antimicrobial treatment modality, categorised as inpatient intravenous antimicrobials, outpatient antimicrobial therapy, early oral antibiotics or lipoglycopeptide. The primary outcome is confirmed completion of planned antimicrobials. We aim to recruit 146 participants over a 2-year period.
EMU has been approved by the Alfred Hospital Human Research Ethics Committee (Project number 78815.) EMU-Audit will collect non-identifiable data with a waiver of consent. EMU-Cohort will collect identifiable data with informed consent. Findings will be presented at scientific conferences and disseminated by peer-review publications.
ACTRN12622001173785; Pre-results.
摘要：
背景：注射药物（PWID）的人有侵入性感染的风险，例如血流感染，心内膜炎,骨髓炎和化脓性关节炎。这种感染需要长期的抗生素治疗，但是关于向该人群提供最佳护理模式的证据有限。使用药物的人的侵袭性感染的流行病学和管理（EMU）研究旨在（1）描述当前的负担，临床谱，PWID中侵入性感染的管理和结局;(2)确定当前可用的护理模式对完成因侵入性感染而入院的PWID的计划抗菌药物的影响;(3)确定因侵入性感染而入院的PWID在30天和90天时的出院结局.
方法：EMU是一项针对澳大利亚公立医院的前瞻性多中心队列研究，这些医院为具有侵袭性感染的PWID提供护理。所有在过去六个月内注射过药物并被接纳到参与治疗侵入性感染的地点的患者都符合资格。动车组有两个组成部分：（1）动车组审计将从医疗记录中收集信息，包括人口统计，临床表现,管理和结果；(2)EMU-Cohort将通过基线访谈来增强这一点，出院后30和90天，和数据联系检查再入院率和死亡率。主要暴露是抗菌治疗方式，归类为住院静脉内抗菌药物，门诊抗菌治疗，早期口服抗生素或脂糖肽。主要结果是确认完成计划的抗菌药物。我们的目标是在两年内招募146名参与者。
背景：EMU已获得阿尔弗雷德医院人体研究伦理委员会的批准（项目编号78815。)EMU-Audit将在放弃同意的情况下收集不可识别的数据。EMU-Cohort将在知情同意的情况下收集可识别数据。研究结果将在科学会议上发表，并通过同行评审出版物传播。
背景：ACTRN12622001173785；预结果。
方法：EMU是一项针对澳大利亚公立医院的前瞻性多中心队列研究，这些医院为具有侵袭性感染的PWID提供护理。所有在过去六个月内注射过药物并被接纳到参与治疗侵入性感染的地点的患者都符合资格。动车组有两个组成部分：（1）动车组审计将从医疗记录中收集信息，包括人口统计，临床表现,管理和结果；(2)EMU-Cohort将通过基线访谈来增强这一点，出院后30和90天，和数据联系检查再入院率和死亡率。主要暴露是抗菌治疗方式，归类为住院静脉内抗菌药物，门诊抗菌治疗，早期口服抗生素或脂糖肽。主要结果是确认完成计划的抗菌药物。我们的目标是在两年内招募146名参与者。
背景：EMU已获得阿尔弗雷德医院人体研究伦理委员会的批准（项目编号78815。)EMU-Audit将在放弃同意的情况下收集不可识别的数据。EMU-Cohort将在知情同意的情况下收集可识别数据。研究结果将在科学会议上发表，并通过同行评审出版物传播。
背景：ACTRN12622001173785；预结果。
